Table 1.
Clinical demographics of patients with prostate cancer (n = 90).
| Clinical demographics | Value | |
|---|---|---|
| Age, median (range), year | 62.7 (47–74) | |
| Initial PSA, median(range), ng/mL | 9.08 (3.42–37.97) | |
| Gleason score, n (%) | ||
| 6 | 28 (31.1%) | |
| 7 | 54 (60.0%) | |
| 8 | 6 (6.7%) | |
| 9 | 2 (2.2%) | |
| T stage, n (%) | ||
| T2a | 16 (17.8%) | |
| T2b | 5 (5.6%) | |
| T2c | 54 (60.0%) | |
| T3a | 3 (3.3%) | |
| T3b | 12 (13.3%) | |
| Surgical margin, n (%) | ||
| Negative | 84 (93.3%) | |
| Positive | 6 (6.7%) | |
| Intensity of BMP-2 | 62.7 (47–74) | |
| Normal expression | High expression | 17 (18.9%) |
| Moderate expression | 41 (45.6%) | |
| Decreased expression | Weak expression | 26 (28.9%) |
| Absent expression | 6. (6.7%) | |
| Immediate adjuvant hormone treatment | 20 (22.2%) | |
| Biochemical recurrence, n (%) | 36 (40.0%) | |
| Progression to CRPC, n (%) | 4 (4.4%) | |
| Follow-up, mean ± S.D months | 90.39 ± 27.10 | |
PSA = prostate specific antigen; BMP = bone morphogenetic proteins; S.D = standard deviation; CRPC = castration resistance prostate cancer.